Meridian Bioscience (VIVO) Reports Q4 EPS of $0.19, Offers FY21 Guidance
Tweet
Share
E-mailGet Alerts VIVO Hot Sheet
Price: $4.90 +0.62%
Financial Fact:
DILUTED EARNINGS PER COMMON SHARE: 0.13
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
DILUTED EARNINGS PER COMMON SHARE: 0.13
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Meridian Bioscience (NASDAQ: VIVO) reported Q4 EPS of $0.19, versus $0.14 consensus. Revenue for the quarter came in at $64.2 million, versus $59.6 million consensus.
GUIDANCE:
Meridian Bioscience sees FY2021 EPS of $1.14-$1.28, versus the consensus of $1.02. Meridian Bioscience sees FY2021 revenue of $290-310 million, versus the consensus of $249.15 million.
For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c
- INVO Fertility (IVF) Tops Q2 EPS by 105c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
